Improving patient and environmental outcomes in asthma care: Q&A session (Promotional content from AstraZeneca) | GPnotebook TV

This site is intended for UK healthcare professionals

Sign In
This promotional video has been initiated, created, funded and reviewed by AstraZeneca. This promotional video page is intended for UK Healthcare Professionals only and AstraZeneca products will be discussed. The content has been reviewed and approved by the sponsoring company AstraZeneca and the speakers. Editorial support for this video has been provided by OmniaMed Communications. GPnotebook has had no input into the content.

Improving patient and environmental outcomes in asthma care: Q&A session (Promotional content from AstraZeneca)

9 June 2022


When individualising asthma care, patients receive their regular inhaled medication in a way that may fit more easily into their lifestyle or that they may find easier to follow. In this video, respiratory specialists Dr Sarah Elkin and Dr Vince Mak discuss the challenges and opportunities, from identifying suitable patients through to managing acute asthma exacerbations in patients.

Symbicort Turbohaler Licensed Indication

Symbicort® Turbohaler is indicated for adults, adolescents 12 years and older and children aged 6 years and older (100/6 Turbohaler for maintenance therapy only) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonists) is appropriate:

– Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists

– Patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists

Symbicort Turbohaler 400/12 should be used as Maintenance Therapy only. Lower strengths are available for the Symbicort Maintenance and Reliever Therapy regimen (100mcg/6mcg/inhalation Turbohaler, 200mcg/6mcg/inhalation Turbohaler).

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting or by calling 0800 783 0033.

GB-36498 | June 2022

The content of this website is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. Any distribution or duplication of the information contained herein is strictly prohibited.

© Oxbridge Solutions Ltd, 2022


Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

To continue, please confirm that you are a UK healthcare professional.

This account does not have a GPnotebook Pro registration

You need to register for GPnotebook Pro in order to track your activity on GPnotebook TV


You’re now logged in, and the time you spend watching GPnotebook TV episodes will be tracked in your GPnotebook Pro CPD dashboard.

When the time is right, you can visit the dashboard to add reflective notes and claim CPD credits

Log in to track your activity and claim CPD credits

  • If you have registered for GPnotebook Pro, you can now automatically track the videos you watch on GPnotebook TV for CPD purposes
  • Simply log in to GPnotebook TV before watching any videos and your activity will be logged in your GPnotebook Pro dashboard
  • When the time is right, visit your GPnotebook Pro CPD dashboard to add reflections and claim CPD credits
  • A GPnotebook Pro account also provides access to exclusive videos 

Already registered for GPnotebook Pro?

Sign In

Not yet registered for GPnotebook Pro?

GPnotebook Pro is currently available to UK healthcare professionals only